Key Points
- Insider sale: Beth Hecht sold 16,667 XERS shares on Dec. 1 at an average price of $7.01 for $116,835.67, reducing her stake by 1.25% to 1,320,176 shares; she also sold 16,667 shares on Nov. 11 at $7.40.
- Recent financials and stock snapshot: Xeris opened at $6.47, trades around a 50‑day MA of $8.18 and 200‑day MA of $6.70 (52‑week range $3.14–$10.08) with a $1.07B market cap, and last quarter reported $0.00 EPS (miss vs. $0.01) on $74.38M revenue.
- Analyst consensus and ownership: Analysts have a "Moderate Buy" consensus with an average target of $9.58 (notably Oppenheimer set an $18 PT), and institutional/hedge funds own about 42.75% of the company.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.01, for a total transaction of $116,835.67. Following the transaction, the insider owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. The trade was a 1.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Beth Hecht also recently made the following trade(s):
- On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total transaction of $123,335.80.
Xeris Biopharma Stock Performance
Shares of XERS opened at $6.47 on Wednesday. The company has a 50 day moving average price of $8.18 and a 200-day moving average price of $6.70. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $3.14 and a fifty-two week high of $10.08. The stock has a market capitalization of $1.07 billion, a PE ratio of -64.69 and a beta of 0.57.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently commented on XERS shares. Oppenheimer reissued an "outperform" rating and issued a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Zacks Research lowered shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Piper Sandler lifted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a "neutral" rating in a research report on Friday, November 7th. Finally, Wall Street Zen cut shares of Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $9.58.
View Our Latest Analysis on XERS
Hedge Funds Weigh In On Xeris Biopharma
Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Xeris Biopharma by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock valued at $44,522,000 after purchasing an additional 210,581 shares during the last quarter. Geode Capital Management LLC increased its stake in Xeris Biopharma by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock valued at $17,052,000 after purchasing an additional 244,862 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company's stock worth $26,657,000 after buying an additional 185,063 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after buying an additional 369,420 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
